Berg & Berg Enterprises

BERG was a clinical-stage biotechnology company that pioneered the use of artificial intelligence in drug discovery through its proprietary Interrogative Biology® platform. By mapping the network of proteins, metabolites, and lipids in human cells, the company identified novel therapeutic targets and biomarkers for oncology, neurology, and rare diseases. Its lead asset, BPM 31510, is a small molecule that targets the metabolic environment of cancer cells to induce apoptosis. In January 2023, BERG was acquired by BPGbio, which continues to develop its AI-driven pipeline and technology. The company was headquartered in Framingham, Massachusetts, and maintained significant research collaborations with academic and government institutions.